Gck 100 mg (DrugBank: -)
1 disease| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 46 | 悪性関節リウマチ | 1 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03755258 (ClinicalTrials.gov) | March 16, 2017 | 21/11/2018 | Trial of Ginsenoside Compound K (GCK) Tablet in Patients With Rheumatoid Arthritis | A Phase Ib Study to Evaluate the Safety, Efficacy and Pharmacokinetics of GCK in Rheumatoid Arthritis Patients | Early Rheumatoid Arthritis | Drug: GCK 100 mg + Placebo 200 mg;Drug: GCK 200 mg + Placebo 100 mg;Drug: GCK 300 mg;Drug: Placebo 300mg | Zhejiang Hisun Pharmaceutical Co. Ltd. | NULL | Unknown status | 18 Years | 65 Years | All | 128 | Phase 1 | China |